With global life expectancy steadily increasing, the growing gap between lifespan and healthspan has placed the aging of the female reproductive system at the forefront of biomedical research. This process, which profoundly impacts fertility, quality of life, and long-term health, is no longer viewed simply through the lens of chronological age or menopause. Instead, a paradigm shift is underway, where aging is understood as a distinct biological process best quantified by multi-omics technologies and computational models known as "aging clocks." These tools—encompassing epigenetics, transcriptomics, proteomics, metabolomics, and microbiomics—provide a powerful, integrated framework to measure biological age, reveal tissue-specific vulnerabilities, and elucidate systemic aging patterns that chronological metrics fail to capture. While this research area is still evolving, the growing availability of high-quality datasets offers unprecedented opportunities to advance our understanding of reproductive aging, infertility, and pregnancy complications, moving towards more personalized and predictive healthcare.
Aging across the entire female reproductive tract is characterized by a convergence of shared biological hallmarks, primarily driven by the decline in estrogen, the accumulation of cellular senescence, oxidative stress, and a state of chronic, low-grade inflammation. Ovarian aging represents the central and most consequential event, marked by the depletion of the ovarian follicle reserve and a decline in oocyte quality. This process is accelerated by mechanisms like mitochondrial dysfunction, genomic instability, and specific epigenetic alterations. The consequences extend far beyond fertility, increasing systemic risks for conditions such as osteoporosis and cardiovascular disease post-menopause. Parallel degenerative changes occur throughout the lower reproductive tract. In the uterus, estrogen deficiency leads to tissue atrophy, increased collagen deposition, and fibrosis, impairing endometrial receptivity. Cervical aging involves epithelial thinning and immune senescence, heightening vulnerability to infections like HPV. In the vagina, these changes manifest as the genitourinary syndrome of menopause (GSM), featuring atrophy, dryness, and dysbiosis. A critical insight from multi-omics research is the bidirectional communication between different systems, particularly through the gut-ovary axis. Local vaginal dysbiosis, characterized by a loss of protective Lactobacillusspecies, and gut microbiome alterations can promote a pro-inflammatory state. This inflammation, along with microbial metabolites, can signal to the ovary, potentially accelerating follicular atresia and functional decline, thereby linking pelvic microenvironment health directly to the pace of reproductive aging.
Each category of omics data contributes a unique and complementary perspective to building a comprehensive picture of biological aging. Epigenetic clocks, such as the widely used Horvath and GrimAge clocks, analyze DNA methylation patterns at specific CpG sites. They provide a stable, cumulative record of long-term molecular aging and are effective for predicting longitudinal outcomes like the rate of ovarian reserve loss, as they are relatively insensitive to rapid hormonal fluctuations across the menstrual cycle. Transcriptomic clocks​ and associated single-cell and spatial transcriptomic atlases offer a dynamic, high-resolution view. Tools like RAPToR estimate biological age from gene expression data, revealing cell-type-specific functional decline—for example, pinpointing downregulated genes in aging granulosa cells. Spatial transcriptomics adds the crucial dimension of tissue architecture, showing how aging signatures are localized within an organ. Proteomic and metabolomic clocks​ track functional and metabolic changes closer to the phenotypic level. Plasma proteomic profiles can predict organ-specific aging trajectories and are strongly correlated with clinical outcomes like physical and cognitive decline. Metabolomic clocks, such as the MetaboAgeMort, utilize circulating metabolites (e.g., specific lipids and amino acids) to create highly predictive models of biological age and short-term mortality risk. Finally, microbiome-based clocks​ profile the dynamic interface between the host and its environment. Models trained on gut, vaginal, or skin microbiota can predict chronological age and detect accelerated "microbial aging," which is often linked to dysbiosis. In the reproductive context, these clocks non-invasively reflect how shifts in microbial communities influence local estrogen metabolism, immune tone, and inflammation, thereby impacting ovarian function and endometrial health.
The ultimate translational promise lies in the integration of these diverse multi-omics datasets into sophisticated, multimodal aging clocks. Such composite models would move beyond merely estimating a number to providing a multidimensional health dashboard for the female reproductive system. This systems-level approach can identify key drivers and biomarkers of conditions like premature ovarian insufficiency (POI), polycystic ovary syndrome (PCOS), recurrent implantation failure, and pelvic organ prolapse. It also illuminates potential therapeutic avenues, from metabolic reprogramming via mTOR inhibition and senolytic therapies to clear aged cells, to microbiome modulation with probiotics and precision molecular interventions targeting specific pathways like fibrosis. By decoding the complex molecular language of reproductive aging, multi-omics research is forging a path toward early risk identification, targeted prevention, and truly personalized interventions designed to preserve not just fertility, but overall healthspan and quality of life for women.
DOI:10.1007/s11684-026-1207-1